**Diphtheria in Metro Manila, the Philippines 2006-2017: A clinical, molecular and spatial characterisation**

Running Title: Diphtheria in Manila, the Philippines

Nobuo Saitoa,b,c PhD, Virginia O. Dimapilisd MD, Hiroshi Fujiib MD, Motoi Suzukia,b PhD, Elizabeth Freda O. Teland PhD, Dorcas Valencia Umipigd MD, Rontgene M. Solanted MD, Alexis Q. Dimapilisd MD, Ferdinand De Guzmand MD, Eumelia P. Salvad MD, Fumihito Nakayamae MD, Kohei Todaf MD, Chris Smitha,g PhD, Koya Ariyoshia,b PhD, Christopher M. Parrya,h,i PhD

Affiliations

a School of Tropical Medicine and Global Health, Nagasaki University, Japan

b Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan

c Department of Microbiology, Faculty of Medicine, Oita University, Oita, Japan

d San Lazaro Hospital, Manila, the Philippines

e Inoue Hospital, Shunkaikai, Nagasaki, Japan

f Philippines Country Office, World Health Organization, Manila, Philippines

g Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom

h Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom

iClinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

Key Words: Diphtheria, the Philippines, Diphtheria antitoxin, MLST, vaccination

Corresponding author

Christopher M Parry, FRCP, PhD

Department of Clinical Infection, Microbiology and Immunology, Institute of Infection and Global Health, Ronald Ross Building, University of Liverpool, Liverpool, UK

E-mail: cmparry@liverpool.ac.uk

Telephone: + 44 (0)151 228 4811 Ext 2736 or + 81-(0)95-819-7842

Fax: +81-(0)95-819-7843

Alternate corresponding author

Dr Nobuo Saito

School of Tropical Medicine and Global Health, Nagasaki University, Japan

Sakamoto 1-12-4, Nagasaki 852-8523, Japan

E-:mail: [nobuosaito@oita-u.ac.jp](mailto:nobuosaito@oita-u.ac.jp)

Telephone: +81-(0)95-819-7842

Fax: +81-(0)95-819-7843

Word Count

Summary 40

Abstract 239

Text 2776

**Summary**

We studied 267 patients with diphtheria hospitalised in Metro Manila over 11 years. Case Fatality Rate was 43·8%, higher in children <10 years, those with delayed treatment or who did not receive diphtheria antitoxin. Cases were widely distributed without clustering.

**Abstract**

**Background.** Diphtheria is a vaccine-preventable disease that persists as a global health problem. An understanding of the pattern of disease is lacking in low- and middle-income countries such as the Philippines.

**Methods.** We conducted a retrospective review of the clinical, microbiological and epidemiological features of patients admitted with a clinical diagnosis of diphtheria to an infectious disease referral hospital in Metro Manila, the Philippines between 2006 and 2017. Cases were mapped and the distribution was compared with population density. *Corynebacterium diphtheriae* isolates from between 2015 and 2017 were examined by multilocus sequence typing (MLST).

**Results.** We studied 267 patients (range:12−54 cases/year) admitted between 2006 and 2017. The Case Fatality Rate (CFR) was 43·8% (95% CI 37·8−50·0). A higher number of cases and CFR was observed among children <10 years. Mortality was associated with a delayed admission to hospital and a lack of diphtheria antitoxin. Between 2015 and 2017 there were 42 laboratory confirmed cases. We identified six multilocus sequence types (STs). ST-302 was the most common (17/34, 48·6%), followed by ST67 (7/34: 20%), and ST458 (5/34: 14%). Case mapping showed a wide distribution of diphtheria patients in Metro Manila. Higher case numbers were found in densely populated areas but with no apparent clustering of ST types.

**Conclusions.** Our analysis indicates that diphtheria remains endemic in Metro Manila and that the infection is frequently fatal in young children. Improved vaccine coverage and a sustainable supply of DAT should be prioritised.

**Introduction**

Diphtheria is vaccine-preventable disease that remains a global health problem. Toxigenic *Corynebacterium diphtheriae* can cause an upper respiratory tract infection complicated by cardiac, neurological and renal manifestations associated with a high mortality. Transmission occurs by person-to-person route through close physical contact and respiratory droplet spread[1, 2]. Diphtheria incidence has steadily declined with the introduction of the expanded program on immunisation (EPI) and socioeconomic improvements[1]. Despite these efforts, diphtheria remains endemic in areas with low vaccine coverage, poor hygiene conditions and overcrowding[3, 4]. Recent outbreaks have been reported in Indonesia, Yemen and Myanmar/Bangladesh [4-6].

An EPI programme was established in the Philippines in 1976 with a primary vaccine course of three DPT doses given at 6−10−14 weeks of age[7]. In 2013, a school-based immunisation program was launched for children aged 6−7 years and 11−12 years[7, 8]. WHO estimated the immunisation coverage for the primary series of diphtheria vaccination to be 86% in 2016. To our knowledge, the vaccine coverage for the booster doses in the Philippines has not officially been reported[9]. Despite these efforts, diphtheria cases continue to be reported[10]. According to WHO statistics, there were an average of 56 (Range 0 to 188) annual cases reported between 2006 and 2017. The Philippines Department of Health (DOH) reported 104 to 168 annual cases between 2014 and 2017 [10-12].

We conducted an observational study in the National Infectious Disease hospital (San Lazaro Hospital) in Metro Manila to describe the clinical, microbiological and epdiemiological characteristics of patients attending the hospital with clinically-diagnosed and laboratory-confirmed diphtheria. We also aimed to understand the distributions of diphtheria cases by molecular types in Metro Manila.

**Methods**

We conducted the study at San Lazaro Hospital (SLH), a 500-bed tertiary hospital specialising in infectious diseases in Metro Manila[11]. SLH is the national referral centre treating the largest number of diphtheria cases in the Philippines.

We analysed patients admitted to SLH with a discharge diagnosis of diphtheria (ICD-10 code A36) over an 11.1-year period between January 1, 2006 to February 9, 2017. The clinical diagnosis of diphtheria was based on assessments by two attending physicians and defined as a respiratory illness consisting of pharyngitis, tonsillitis, or laryngitis, and an adherent tonsillar or nasopharyngeal pseudomembrane. Demographic, epidemiological and clinical data including the date of admission, age, sex, home location of the patient, and administration of diphtheria antitoxin (DAT) extracted from the medical records. DAT was not available until March 2016 when the WHO and the DOH started to provide DAT.

In December 2015, the hospital established laboratory methods for *C. diphtheriae* isolation and confirmation and started prospective data collection using structured questionnaire sheets for all patients with clinically suspected diphtheria. We analysed these laboratory-confirmed cases separately. The immunization history was obtained by the questionnaire and we requested family members to present the immunization cards.

Laboratory-confirmed cases were defined as a patient with a positive result of culture for *C. diphtheriae* and/or a tox-gene PCR positive result from throat or nasopharynx swab samples.

Throat or nasopharynx swab specimens were taken at the time of admission from all patients with clinically suspected diphtheria. Brain heart infusion (BHI) broth was used as transport media. The swabs were inoculated to 5% sheep blood agar and selective Hoyle`s agar with potassium tellurite (Oxoid, Cheshire, England). Black suspect colonies on Hoyles media which were Gram-positive bacilli were identified using MALDI Biotyper® (Bruker Daltonics, Bremen, Germany). The Minimum Inhibitory Concentrations (MICs) of penicillin G and erythromycin were determined by E-test strips according to manufacturer’s instruction (Biomerieux, Lyon, France). Isolates were stored in glycerol broth at −80oC for subsequent tox-gene PCR.

We assessed the toxigenicity of the identified isolates by a PCR that detects the tox gene using a published method[13]. Direct toxin gene detection was also performed on the throat swabs. DNA was extracted from the 100μL aliquot of the BHI transport broth using a QIAamp DNA Blood Mini Kit® following manufacturer's instruction (QIAGEN, Hilden, Ger­many). DNA extracted from isolates were stored at −20C°using DNA extraction kit (Wizard Genomic DNA Purification Kit®, Promega, Wisconsin, USA) and transported to Nagasaki, Japan for Multilocus Sequence Typing (MLST) as described by Bolt et al[14]. Sequence types (STs) were assigned by PubMLST database and added to this database (https://pubmlst.org/cdiphtheriae/). We generated a phylogenetic tree by using Molecular Evolutionary Genetics Analysis (MEGA) software version MEGA 7.0.26 (https://www.megasoftware.net/). A mmaximum likelihood tree was constructed using the concatenated sequences (2,544 nucleotides) of the seven loci used in MLST. In the analysis, the publicly available sequence of 56/S (*C.diphtheriae* isolated in Poland, 1950) was added to the alignment as an outlier. We defined a clonal complex as a cluster of isolates sharing six out of seven alleles. Clonal analysis was performed using eBURSTv3 (http://eburst.mlst.net/default.asp). We generated an eBURST diagram of *C. diphtheriae* to show relatedness between isolates in this study and 703 isolates previously registered in PubMLST (https://pubmlst.org/cdiphtheriae/).

We converted the home location of the diphtheria patients in Metro Manila into GPS locations and conducted analysis using GIS software (ArcGIS version. 10.5, ESRI, Redlands, CA). Population data and basic maps were obtained from the PhilGISTM (http://www.philgis.org/gis-data), Philippines Statistics Authority(<https://psa.gov.ph/>),　and EsriTM (<http://www.esri.com/software/arcgis/arcgisonline/features/maps>). We created a case map using GPS location of clinically-diagnosed diphtheria cases between January 2006 and December 2015 and culture-positive diphtheria cases by the sequence types between December 2015 and February 2017. We created a population density map in Metro Manila and compared the distributions of the diphtheria cases with the population density. Kernel density analysis was used to determine hotspot areas of clinically-diagnosed diphtheria cases between January 2006 and December 2015. We compared the distributions of culture-positive diphtheria by sequence types with the hotspot area created with the previously clinically-diagnosed diphtheria cases.

We used Microsoft Access 2010 (Microsoft Corporation, Washington, USA) for the data entry. Each case was given a study-specific identifying number. Statistical analyses were performed using Stata software (version 13; StataCorp, College Station, Texas, USA). We conducted a statistical analysis of patient characteristics using Fisher’s exact test for categorical variables, and the t-test for continuous variables. We calculated risk ratios (RRs) of the effect of variables on fatal outcome using an unadjusted logistic regression model. An adjusted logistic regression model was not used in this study because of the small sample size. Age groups were categorized into 0−4, 5−9, 10−14, 15−20 and over 20 years. We report in accordance with the STROBE statement.

Ethical approval was obtained from the Research and Ethical Review Board of San Lazaro Hospital, the Philippines (Reference number:2016-015-E) and the Institutional Review Board of the Institute of Tropical Medicine, Nagasaki University, Japan (170707169). Both review boards agreed that consent from the patients was not required as this study consists of analysis of data previously collected as part of standard clinical management.

**Results**

Between January 1, 2006 and February 9, 2017, a total of 267 patients (mean 24; range:12−54 cases/year) with clinically diagnosed diphtheria were admitted to SLH (Table 1, Supplementary Figure 1). The majority of cases were children under 15 years old (231 cases:86.5%). Children aged 5−9 years (103 cases: 38.6%) were most common followed by children under five years (83 cases: 31.1%).

A total of 117 patients died in hospital (43.8%, 95% Confidence interval: 37.8−50.0) (Table 1). The case fatality rate (CFR) was highest (60.2%, 48.9−70.8) among children under five years followed by those of 5−9 years (44.7%, 34.9−54.8) (Supplementary Figure 2). The lowest CFR was observed among subjects aged 15−19 years (17.4%, 5.0−38.8). There was no significant difference in the CFR by sex. There was a significantly lower CFR among patients given DAT as part of their clinical management compared to patients not given DAT (103/216 [47.7%, 40.9−54.6] vs. 14/51 [27.5%, 15.9−41.7], P<0.01).

After introducing enhanced laboratory testing in December 1, 2015 there were 68 patients with clinically-diagnosed diphtheria, of whom 42 were confirmed by laboratory testing (Table 2). *C. diphtheriae* was isolated in 35 patients and all isolates had a positive tox-gene PCR result. A further seven patients had a positive tox-gene PCR on the throat swab but a negative culture result. There were 33 (94.3%) isolated strains susceptible to penicillin G (MIC=<0.12 mg/dL) and 2 (5.7%) strains intermediate according to the Clinical Laboratory Standards Institute (CLSI M45 2016) guideline. Most isolates were susceptible to erythromycin, but one isolate was resistant (MIC=2 mg/dL)[15].

We observed 18 deaths among the 42 patients with laboratory-confirmed diphtheria giving a CFR of 42.8% (95%CI: 27.7−59.0). The CFR among children under five years (60%, 32.3−83.7) and aged 5−9 years (80%, 28.4−99.5) was higher compared to patients aged 10−14 years (25%, 5.5−57.2) and 15−19 years (0%) although the confidence intervals were wide due to the small sample size (Supplementary Table 2; Supplementary Figure 3). 33.3% of the patients were living outside Metro Manila and they had significantly higher CFR compared with patients living in Metro Manila (64.3%, 35.1−87.2 vs 32.1%, 15.9−52.4, P=0.049). Patients attending hospital within four days after onset of symptom had significantly lower CFR than those admitted after five days or more (28%,12.1−49.4 vs 64.7%, 38.3−85.8, P=0.03). The RR of death among patients with a chronic disorder compared to patients without a chronic disorder was significantly increased (RR: 2.11 95%CI:1.16−3.86).

Twenty (47.6%) of the 42 laboratory-confirmed diphtheria patients reported having received three primary doses of DPT vaccine but only eight were confirmed by inspection of their immunisation record card. Among the fully-immunised patients confirmed by their immunisation card, there was one death in a nine-year old patient. There was no significant difference in the CFR between subjects with a history of receiving three doses of primary vaccinations than without any history of the vaccine (Table 2). None of the patients reported receiving a booster dose of diphtheria vaccine. All cases were treated with penicillin G. Among the 30 patients who received DAT, 11 (CFR: 36.7%, 19.9−56.1) died compared with seven deaths among the 12 who did not receive DAT due to limited availability (58.3%, 27.7−84.8) (p=0.17).

Among 34 isolates available for MLST testing, a total of seven STs and four isolates without ST identifications were found (Supplementary Table 1). STs of four isolates were not identified because one allelic profile was not generated by PubMLST database. ST-302 was the most common ST type (n=17, 48.6%), followed by ST-67 (7 cases: 20%) and ST-458 (5 cases: 14%). (Supplementary Table 1). One isolate with erythromycin resistance was of unknown ST type and the single locus variant of ST457 and ST-40. Clonal analysis classified seven clonal complexes among the 34 isolates including the four isolates without ST identifications. The Phylogenetic Tree and eBURST diagram did not show a clear relatedness among the seven clonal complexes (Figure 1A and 1B).

Case mapping showed a wide distribution of patients with diphtheria in Metro Manila (Figure) 2. Many diphtheria patients were identified in highly populated areas. Most of the laboratory-confirmed cases in 2015−2017 were resident in areas where clinical diphtheria patients had been observed in the previous eleven years. ST types were scattered around the city with no apparent clustering of ST types.

**Discussion**

Our study showed that diphtheria persists as an important public health problem in Metro Manila. The disease is most common among children under ten years who also have the highest mortality. The introduction of enhanced laboratory capacity showed that laboratory-diagnosed cases occurred in areas where clinical diphtheria cases had been found in the previous ten years. A variety of MLST types are circulating across the city particularly in densely populated areas of the city.

We observed a high number of cases and high CFR among children under ten years. In 2016 and 2017 this was particular marked in children under 5 years. National surveillance conducted by the Department of Health also reported a 20% increase of diphtheria cases in 2016 compared with cases observed in 2015[10]. A contributing factor for this increased incidence in 2016 may be low vaccine coverage during 2014 and 2015. According to WHO and Unicef reports, DPT3 coverage dropped from 89% in 2013 to 67% in 2014 and 60% in 2015, and this may have been due to national level stock-out of vaccine[9]. In most developed countries, EPI led to rapid reductions in diphtheria incidence among children [3]. Toxigenic respiratory diphtheria among young children often occurs in areas where vaccine coverage is not sufficient[3, 16]. These findings suggest the need to strengthen and sustain vaccine coverage in this area.

Several factors may have contributed to the higher CFR in our study compared with those of other reports [17-20]. This hospital is a tertiary medical institution so many cases were severe by the time of referral. Milder cases are likely to have been treated in local health facilities possibly without the clinical suspicion of diphtheria. Delayed treatment was observed in many cases and significantly associated with a higher CFR in our study. The CFR was significantly lower among DAT recipients compared with those without DAT treatment. Administration of DAT contributes to reducing mortality[21]. Early administration is critical because DAT is not able to neutral the toxin once toxin has entered host cells (particularly myocardial cells)[22]. DAT had not been reliably available in this hospital for the past ten years. Since March 2016, WHO provided DAT through DOH in the Philippines[11]. A sustainable and secure supply of DAT needs to be maintained.

The CFR among those with a history of receiving three doses of primary vaccination course was not significantly lower than those with no history of receiving the vaccine. Other studies have shown a strong association between unvaccinated status and death[23, 24]. The different result in this study may have been caused by misclassification of vaccine status due to recall bias. Only eight patients were able to confirm their vaccine status with their immunisation record card. Three patients were aged under five years and the others were aged 10−14 years. The finding of immunized individuals having severe toxigenic diphtheria aged in these age-groups indicates the need to consider enhancements of school-age booster but also booster dose for children under five years.

Various molecular types of diphtheria were found in this study with a wide distribution across Metro Manila. There was no apparent clustering although we observed overlapping distributions between diphtheria patients and densely populated areas of Metro-Manila (Figure 2). ST-302 is the major ST type in Manila followed by ST-67 and ST-458. ST-302 and ST-67 were also found outside Metro Manila and widely scattered distributions of same ST inside Metro Manila were observed. The phylogenetic tree and eBURST diagram showed seven distinct clonal complexes with no apparent clusters. In the MLST database, these ST types have also been reported in other continents (ST-302: Germany with travel history to Malaysia, ST-67: France, Belgium, ST-458: Malaysia, ST-457: Malaysia, ST-497: Germany, ST-499: Germany). Although our study was unable to compare molecular type with older isolates, it is possible that the same strains of diphtheria have been circulating for a long time in the area. One study reported an outbreak strain circulating in the same area over decades[14]. The genome of Corynebacterium species is stable and genome rearrangements rarely occur[25, 26].

Our study has limitations. We studied patients attending a single hospital in Metro Manila which may not reflect the true situation across the city. It is likely that the burden of disease is underestimated as mild cases may not be referred to this hospital. All laboratory-confirmed cases in this study were respiratory toxigenic diphtheria. Cutaneous diphtheria and chronic rhinitis (ozenae) were not included in this study and are probably underdiagnosed in this area. We did not identify the biotype of the isolates but consider that MLST is more helpful in understanding the epidemiology of the infection[27]. We performed tox-gene PCR but did not perform Elek`s test to determine the toxigenicity of the isolates. Tox-gene PCR alone is not able to provide a definitive confirmation of toxin production but the bacteria were isolated from patients with the clinical picture of symptomatic respiratory diphtheria. E-tests are not the recommended method for MIC testing[15]. The diagnostic capacity for diphtheria in the Philippine is limited. A recent global survey on diphtheria diagnostic capacity conducted by WHO showed significant gaps in the capacity exist in Western Pacific Region. WHO collaborating center for diphtheria recently conducted a hands-on laboratory training for diphtheria to build capacity in the laboratory diagnosis in the region [28]. To improve the diphtheria surveillance, it is necessary to strengthen diagnostic capacity in the Philippines.

Our study revealed that diphtheria persists as a public health problem in Metro Manila, the Philippines causing preventable childhood deaths. Renewed efforts to improve vaccine coverage of the primary course of DPT are needed, as well as consideration of an additional booster dose for children under five years, encouraging education and awareness for early detection and treatment and ensuring a sustainable supply of DAT.

**Acknowledgements**

We gratefully acknowledge the Director and staff of San Lazaro Hospital for their support in the conduct of this study.

**Contributions**

NS, VOD and CMP proposed the study idea. NS, MS, KA, CS and CMP contributed to the literature review. The study was designed by NS, VOD, MS, KA and CMP. Data collection was done by NS, VOD, EFOT, UDV, RMS, AQD, FDG, and EPS. Data analysis was done by NS, FH, MS, CS, KA and CMP. Molecular analysis was done by NS and FH. Figures were created by NS, FH, MS, and CMP. All authors contributed to the writing of the final report.

**Declaration of interests**

We declare no competing interests.

**Funding**

This work was supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Government of Japan. The funders had no role in the study design, data collection and analysis, decision to publish or reparation of the manuscript.

**References**

1. World Health Organization. Diphtheria vaccine: WHO position paper – August 2017. **2017;**417-36.

2. Tiwari TSP and Wharton M. Chapter 19: Diphtheria toxoid. in Plotkin’s Vaccines. Seventh Edition:261–275 ed. **2017**.

3. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis, **2000**; 181 Suppl 1: S2-9.

4. Hughes GJ, Mikhail AF, Husada D, et al. Seroprevalence and determinants of immunity to diphtheria for children living in two districts of contrasting incidence during an outbreak in East Java, Indonesia. Pediatr Infect Dis J, **2015**; 34: 1152-6.

5. Reliefweb OCHA. Diphtheria vaccination campaign for 2.7 million children concludes in Yemen . Available at: <https://reliefweb.int/report/yemen/diphtheria-vaccination-campaign-27-million-children-concludes-yemen>. Accessed May 18th, 2018.

6. Rahman MR, Islam K. Massive diphtheria outbreak among Rohingya refugees: Lessons learnt. J Travel Med, **2019**; 26: 10.1093/jtm/tay122.

7. Department of Health in the Philippines. Expanded program on immunization. Available at: <https://www.doh.gov.ph/expanded-program-on-immunization>. Accessed April 10th, 2018.

8. Department of Health in the Philippines. Guidelines on the implementation of school-based immunization. **2015;** No.2015-0146. Available at: https://www.doh.gov.ph/sites/default/files/health\_programs/DM%202015-0146%20Guidelines%20on%20the%20Implementation%20of%20School-Based%20Immunization.pdf. Accessed April 10th, 2018.

9. WHO and UNICEF. Philippines: WHO-UNICEF estimates of DTP3 coverage: 2016 version. **2017;**. Available at: http://apps.who.int/immunization\_monitoring/globalsummary/timeseries/tswucoveragedtp3.html. Accessed April 10th, 2018.

10. Department of Health in the Philippines. Statistics, Disease Surveillance, Diphtheria. 2018; Available at: https://www.doh.gov.ph/statistics. Accessed April 2nd, 2018.

11. WHO Representative Office Philippines. Lessons learned from recent diphtheria cases . Available at: <http://www.wpro.who.int/philippines/mediacentre/features/lessons_learned_diphtheria_cases/en/>. Accessed April 10th, 2018.

12. WHO. Diphtheria reported cases by country. Available at: <http://apps.who.int/gho/data/view.main.1540_41?lang=en>. Accessed April 10th, 2018.

13. Nakao H, Popovic T. Development of a direct PCR assay for detection of the diphtheria toxin gene. J Clin Microbiol, **1997**; 35: 1651-5.

14. Bolt F, Cassiday P, Tondella ML, et al. Multilocus sequence typing identifies evidence for recombination and two distinct lineages of *Corynebacterium diphtheriae*. J Clin Microbiol, **2010**; 48: 4177-85.

15. CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed CLSI guideline M45. Wayne, PA: Clinical and laboratory standards institute;**2016**.

16. Galazka AM, Robertson SE, Oblapenko GP. Resurgence of diphtheria. Eur J Epidemiol, **1995**; 11: 95-105.

17. Dobie RA, Tobey DN. Clinical features of diphtheria in the respiratory tract. JAMA, **1979**; 242: 2197-201.

18. Niyazmatov BI, Shefer A, Grabowsky M, Vitek CR. Diphtheria epidemic in the republic of Uzbekistan, 1993-1996. J Infect Dis, **2000**; 181 Suppl 1: S104-9.

19. Jogiste A, Ching P, Trei T, Kreysler J. Diphtheria in Estonia, 1991-1996. J Infect Dis, **2000**; 181 Suppl 1: S65-8.

20. Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz republic, 1995. J Infect Dis, **2000**; 181 Suppl 1: S110-5.

21. Park WH, Atkinson JP. The relation of the toxicity of diphtheria toxin to its neutralizing value upon antitoxin at different stages in the growth of culture. J Exp Med, **1898**; 3: 513-32.

22. Sein C, Tiwari T, Macneil A, et al. Diphtheria outbreak in Lao people's democratic republic, 2012-2013. Vaccine, **2016**; 34: 4321-6.

23. Kneen R, Nguyen MD, Solomon T, et al. Clinical features and predictors of diphtheritic cardiomyopathy in Vietnamese children. Clin Infect Dis, **2004**; 39: 1591-8.

24. Jayashree M, Shruthi N, Singhi S. Predictors of outcome in patients with diphtheria receiving intensive care. Indian Pediatr, **2006**; 43: 155-60.

25. Nakamura Y, Nishio Y, Ikeo K, Gojobori T. The genome stability in corynebacterium species due to lack of the recombinational repair system. Gene, **2003**; 317: 149-55.

26. Mokrousov I. *Corynebacterium diphtheriae*: Genome diversity, population structure and genotyping perspectives. Infect Genet Evol, **2009**; 9: 1-15.

27. Sangal V, Hoskisson PA. Evolution, epidemiology and diversity of *Corynebacterium diphtheriae*: New perspectives on an old foe. Infect Genet Evol, **2016**; 43: 364-70.

28. WHO Regional Office for the Western Pacific. Meeting Report. 27th Meeting of the technical advisory group (TAG) on immunization and vaccine-preventable diseases in the western pacific region. October **2018**. Available at: <https://iris.wpro.who.int/bitstream/handle/10665.1/14309/RS-2018-GE-98-PHL-eng.pdf> Accessed October 10th, 2019.

**Table 1**

A comparison of the characteristics of patients admitted to San Lazaro Hospital, Manila, the Philippines with clinically diagnosed diphtheria between January 1 2006 and February 9 2017 according to whether they survived or died

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | Total No. | Survived No | Died No. | Mortality (%) | P value |
| Total  (January 2006 ~ Feb 2017) a | | 267 | 150 | 117 | 43·8 |  |
| Sex | | | | | | |
|  | Female | 145 (54·3) | 82 | 63 | 43·5 | 0·902 |
| Male | 122 (45·7) | 68 | 54 | 44·3 |
| Age Group (years) | | | | | | |
|  | < 5 | 83 (31·1) | 33 | 50 | 60·2 | <0·01 |
| 5 - 9 | 103 (38·6) | 57 | 46 | 44·7 |
| 10 - 14 | 45 (16·9) | 34 | 11 | 24·4 |
| 15 - 19 | 23 (8·6) | 19 | 4 | 17·4 |
| ≥ 20 | 13 (4·9) | 7 | 6 | 46·2 |
| DAT treatment given during the admission | | | | | | |
|  | DAT not given | 216 (80·9) | 113 | 103 | 47·7 | <0·01 |
| DAT given | 51 (19·1) | 37 | 14 | 27·5 |

Data are n, n(%). RR=Risk ratio. DAT=Diphtheria antitoxin. Y=years. a The observation period is 11·1 year between 1st January 2006 and 9th February 2017.

**Table 2**

Characteristics of Laboratory-Confirmed Diphtheria Patients admitted to San Lazaro Hospital, Manila, the Philippines between December 1 2015 and February 9 2017 according to whether they survived or died

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | Total No. | Survived No. | Died No. | Mortality (%) | P value | RR |
| Totala | | 42 | 24 | 18 | 42·8 |  |  |
| Culture positive | | 35 | 19 | 16 | 45·7 |  |  |
| PCR positive (n=34) | | 31 | 19 | 12 | 38·7 |  |  |
| Sex | | | | | | | |
|  | Male | 17 | 9 | 8 | 47·1 | 0·755 | 1.18 (0·59:2·36) |
| Female | 25 | 15 | 10 | 40 | Ref |
| Age Group (Years) | | | | | | | |
|  | < 5 | 15 | 6 | 9 | 60 | 0·154 | 2·34 (0·82:7·04) |
| 5 - 9 | 5 | 1 | 4 | 80 | 3·20 (1·08:9·48) |
| 10 - 14 | 12 | 9 | 3 | 25 | Ref |
| 15 - 19 | 7 | 7 | 0 | 0 | N/A |
| ≥ 20 | 3 | 1 | 2 | 66·8 | 2·67 (0·74:9·60) |
| Living areab | | | | | | | |
|  | Metro Manila | 28 | 19 | 9 | 32·1 | <0·05 | Ref |
| Outside Metro Manila | 14 | 5 | 9 | 64·3 | 2·00 (1·03:3·89) |
| Duration of symptom (Days) | | | | | | | |
|  | 1-4 | 25 | 18 | 7 | 28 | <0·05 | Ref |
| ≥ 4 | 17 | 6 | 11 | 64·7 | 2·31 (1·12:4·75) |
| Underlying chronic disorders | | | | | | | |
|  | Any | 5 | 1 | 4 | 80 | 0·096 | Ref |
| Not present | 37 | 23 | 14 | 37·8 | 2·11 (1·16:3·86) |
| Number of DPT dose(s) | | | | | | | |
|  | 0 | 11 | 9 | 2 | 18·2 | 0·082 | Ref |
| 1 or 2 | 4 | 1 | 3 | 75 | 4·13 (1·03:16·6) |
| 3 | 20 | 12 | 8 | 40 | 2·2 (0·55:8·74) |
| Unknown/No record | 7 | 2 | 5 | 71·4 | 3·93 (1·01:15·2) |
| DAT treatments given during the admission | | | | | | | |
|  | DAT given | 30 | 19 | 11 | 36·7 | 0·17 | 0·62 (0·32:1·23) |
| DAT not given | 12 | 5 | 7 | 58·3 | Ref |

Data are n, n(%). RR=Risk ratio. DAT=Diphtheria antitoxin. Y=years. Ref=Reference. N/A=Not Applicable. a The observation period is 1·2 year between 1st December 2015 and 9th February 2017. b San Lazaro Hospital is located in Metro Manila. Other data including symptoms, vital signs and electrocardiogram finding are shown in supplemental table

**Figure Legends**

**Figure 1(A).**

Phylogenetic Tree of *Corynebacterium diphtheriae* isolates based on Multilocus Sequence Types (STs) among Patients Admitted in San Lazaro Hospital (SLH) December 2015 and Februa 2017. \* STs were not identified but S244/Quezon/Philippines/2016 is the single locus variant(SLV) of ST-302. S1165/Manila/Philippines/2017 and S1166/Cavite/Philippines/2017 were SLVs of ST457.

**Figure 1(B).**

eBURST diagram demonstrate the relatedness of isolates in this study and 702 of isolates as reference STs from the MLST website (http://pubmlst.org/cdiphtheriae/ Access 15/December/2018). The primary founder STs are shown in grey and subgroup founder STs are shown in black. The STs isolated in our study and SVLs of unidentified STs in our study are indicated with red and blue halos, respectively.

**Figure 2.**

The spatial distribution of clinical and laboratory confirmed diphtheria cases in Metro Manila.

**Figure 2 (A).**

The home location of the clinically-diagnosed diphtheria cases between January 1 2006 and November 30 2015 (yellow dots) and culture-positive diphtheria cases by the Multilocus Sequence Type (ST) between December 1 2015 and February 9 2017 overlaid on a population density map of Metro Manila.

**Figure 2 (B).**

The home location of the culture positive diphtheria cases by the Multilocus Sequence Types between December 1 2015 and February 9 2017 overlaid on a Hotspot map created using the clinically-diagnosed diphtheria cases between January 1 2006 and November 30 2015.